The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Hepatitis B Surface Antigens

Hepatitis B Surface Antigens

Hepatitis B Surface Antigens (HBsAg) are proteins found on the surface of the hepatitis B virus (HBV).
These antigens are a key diagnostic marker for HBV infection and are used to monitor disease progression and treatment response.
Accurate detection and quantification of HBsAg is crucial for effective management of hepatitis B.
PubCompare.ai's AI-driven platform can help researchers optimize their HBsAg research protocols by providing access to relevant literature, pre-prints, and patents, along with AI-powered comparisons to identify the best methods and products.
This simplified approach to Hepattis B research can streamline your workflow and improve your investigations into this important viral marker.

Most cited protocols related to «Hepatitis B Surface Antigens»

Besides a clinical and laboratory evaluation, each subject underwent a liver ultrasonography, an anthropometric assessment and a 7-day diary of food intake (7DD) [1 (link)]. HBsAg and anti-HCV antibodies were assessed and subjects with anti-HCV antibodies underwent an HCV-RNA assessment to confirm HCV infection [1 (link),14 (link)]. ALT, aspartate transaminase (AST), GGT, glucose, triglycerides and cholesterol were measured by standard laboratory methods after 8-hr fasting. Insulin was measured by radio-immuno-assay (ADVIA Insulin Ready Pack 100, Bayer Diagnostics, Milan, Italy), with intra- and inter-assay coefficients of variation < 5%. FL was diagnosed by the same operator at ultrasonography [6 (link)]. Weight, stature, circumferences (waist and hip) and skinfolds (triceps, biceps, subscapular and suprailiac) were measured by two trained dietitians who had been standardized before and during the study according to standard procedures [15 ]. Body mass index (BMI) was calculated as weight (kg)/stature (m)2 and the sum of 4 skinfolds by summing triceps, biceps, subscapular and suprailiac skinfolds [16 (link),17 (link)]. The 7DD was administered to the subjects by two trained dietitians, who discussed it with the subject when she/he returned it one week later [18 (link)]. To avoid the confounding effect of seasonality on food intake, the 7DD diary was administered to a similar number of patients with and without SLD each month [19 ]. Mean daily ethanol intake was calculated as the mean value of ethanol intake as assessed by the 7DD [20 ]. The study protocol was approved and supervised by the Scientific Committee of the Fondo per lo Studio delle Malattie del Fegato (Trieste, Italy), and all subjects gave their written informed consent to participate.
Full text: Click here
Publication 2006
Aspartate Transaminase Biological Assay Body Height Cholesterol Dietitian Eating Ethanol Glucose Hepatitis B Surface Antigens Hepatitis C Hepatitis C Antibodies Index, Body Mass Insulin Liver Patients Radioimmunoassay Triglycerides Ultrasonography
The protocol of the Dionysos Nutrition & Liver Study was described in detail elsewhere [1 (link)]. Briefly, of 5780 residents of Campogalliano (Modena, Italy) aged 18 to 75 years, 3345 (58%) agreed to participate to the study; 3329 (99%) of them had all the data required by the Dionysos Project [7 (link),13 (link)] and were considered for further analysis. 497 (15%) of them had suspected liver disease (SLD) according to at least one of the following criteria: 1) alanine transaminase (ALT) > 30 U*L-1; 2) gamma-glutamyl-transferase (GGT) > 35 U*L-1; 3) presence of hepatitis B surface antigen (HBsAg); 4) presence of Hepatitis C (HCV) virus ribonucleic acid (RNA) after detection of anti-HCV antibodies. The 497 subjects with SLD were matched with an equal number of subjects of the same age and sex but without SLD, randomly selected among the remaining 2832 subjects. After exclusion of subjects with HBV or HCV infection, the original analysis was performed on 224 subjects with and 287 without SLD [1 (link)]. The present analysis is performed on 216 (96%) subjects with and 280 (97%) without SLD, based on the availability of skinfold measurements.
Full text: Click here
Publication 2006
Alanine Transaminase gamma-Glutamyl Transpeptidase Hepatitis B Surface Antigens Hepatitis C Hepatitis C Antibodies Liver Diseases Liver Function Tests RNA Virus
The Demo Project enrolled participants from municipal STI clinics in San Francisco and Miami and a community health center in Washington, DC from October 2012 to January 2014. These clinics have access to large populations of at-risk MSM, with annual HIV seroconversion rates of 2.3%-4%.13 (link) Participants were eligible if they were male at birth and 18 years or older; fluent in English or Spanish; had a negative rapid HIV antibody test at screening and enrollment and a negative 4th generation antibody/antigen (Ag/Ab) test at screening; had creatinine clearance ≥60 ml/min and a urine dipstick with negative or trace protein; and reported any of the following in the last 12 months: condomless anal sex with ≥2 male or transgender female partners; ≥2 episodes of anal sex with ≥1 HIV-infected partner; or sex with a male/transgender female partner and having a diagnosis of syphilis or rectal gonorrhea or chlamydia. Individuals with serious active medical conditions, a history of pathologic fracture, hepatitis B surface antigen positivity, or taking nephrotoxic medications were excluded. Written informed consent was obtained at screening, and eligible individuals returned for enrollment and were dispensed one month of TDF/FTC. The sample size allowed us to estimate proportions within margins of sampling error of +/− 4.4%, and to detect adjusted odds ratios of 1.7-2.3, depending on predictor and outcome prevalence.
Participants returned for clinic visits at 4, 12, 24, 36, and 48 weeks for HIV/STI testing, clinical monitoring, and PrEP dispensing. Participants were encouraged to return 4 weeks after stopping PrEP for a final evaluation and HIV test. Brief, client-centered counseling was provided at all visits [eMethods1]. Retention procedures were limited, with up to 3 contact attempts after a missed visit. Participants received $25 for each scheduled visit. PrEP was discontinued in seroconverters, who received counseling, partner services, and linkage to HIV primary care. TDF/FTC PrEP (donated by Gilead Sciences) and HIV/STI testing and safety monitoring (supported by the clinic or study funds) were provided free to participants. Among the 3 study sites, only the DC site offered PrEP outside the Demo Project. The protocol was approved by local institutional review boards.
Publication 2016
Antibodies Antigens Anus Chlamydia Creatinine Diagnosis Ethics Committees, Research Gonorrhea Hepatitis B Surface Antigens Hispanic or Latino Male Genital Organs Males Pathological Fracture Pharmaceutical Preparations Population at Risk Primary Health Care Proteins Rectum Retention (Psychology) Safety Syphilis Testing, AIDS Transgendered Persons Urine Woman

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Boys Child Diagnosis Enzyme Immunoassay Fatty Liver Glucose Hepatitis B Surface Antigens Hepatitis C Antibodies Hepatitis Viruses HIV-1 HIV-2 HIV Antibodies Hypoalphalipoproteinemias Immunoblotting Insulin Iron Overload Liver Diseases Non-alcoholic Fatty Liver Disease Obesity Peptides Pharmaceutical Preparations Ribavirin Serum Transferrin Triglycerides Western Blotting Woman

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
Adult Antiviral Agents Bone Marrow Transplantation Chronic Infection Coinfection Disease Progression Hepatitis A Hepatitis B Surface Antigens HIV Patients Therapeutics Vision Woman

Most recents protocols related to «Hepatitis B Surface Antigens»

This study included patients who participated in the Cohort of Non-alcoholic Fatty Liver Disease in Saudis with T2DM (the CORDIAL Study). This prospective cohort study started in 2015 and recruited patients from King Fahad Medical City (KFMC) and affiliated Primary Care Centers in Riyadh, Saudi Arabia. The cohort was approved by the Institutional Review Board at KFMC (study number: 12–344), and all patients provided written, informed consent prior to recruitment. The study was conducted in accordance with the ethical principles for medical research on human subjects adopted by the 18th World Medical Association General Assembly, and the Declaration of Helsinki 1964 and its subsequent amendments. The inclusion criteria included Saudi patients aged 18–60 years who were diagnosed with T2DM and followed up regularly in the diabetes or primary care clinics. Patients were excluded if they tested positive for hepatitis B surface antigen or had antibodies against hepatitis C virus, were diagnosed with other chronic liver diseases (e.g., hemochromatosis, primary biliary cholangitis, or autoimmune hepatitis), known to have pre-existing hepatic or extrahepatic malignancy, or were consuming >20 g of alcohol per day. The patients will be prospectively followed for 10 years and assessed for hepatic, metabolic, renal, and cardiovascular complications.
Full text: Click here
Publication 2023
Autoimmune Chronic Hepatitis Cardiovascular System Diabetes Mellitus Disease, Chronic Ethanol Ethics Committees, Research Hemochromatosis Hepatitis B Surface Antigens Hepatitis C Antibodies Kidney Liver Malignant Neoplasms Non-alcoholic Fatty Liver Disease Patients Primary Biliary Cholangitis Primary Health Care
Liver biochemical parameters were determined by a biochemistry analyzer (7600 Series; Hitachi, Tokyo, Japan). Platelet was measured by Sysmex XN-2000 (Kobe, Japan). Serum HBsAg, anti-HBs, hepatitis B e antigen (HBeAg), hepatitis B e antibody (anti-HBe), and hepatitis B core antibody (anti-HBc) were detected using an enzyme-linked immunosorbent assay kit (ARCHITECT i2000 SR; Abbott Architect, USA). Serum HBsAg were retested (Roche Cobas e602; Roche, Switzerland) when it exceeded the upper linearity limit (250 IU/mL). HBV DNA was quantified by using a real-time PCR assay (DAAN Diagnostics, Guangzhou, China). Detection limits of HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, and HBV DNA were 0.05 IU/mL, 10 IU/L, 1 S/CO, 1 S/CO, 1 S/CO, 500 IU/mL, respectively. The upper limit of normal (ULN) of ALT has been defined as 40 U/L for women and 50 U/L for men. The ULN of bilirubin has been defined as 21 μmol/L for women and 26 μmol/L for men. The normal range of albumin was 40-55 g/L. In addition, hepatitis B core-related antigen (HBcrAg) was not detected due to the lack of serum samples.
Full text: Click here
Publication 2023
Albumins Bilirubin Biological Assay Blood Platelets Diagnosis Enzyme-Linked Immunosorbent Assay Hepatitis B Antibodies Hepatitis B Core Antigen Hepatitis B e Antigens Hepatitis B Surface Antigens Liver Real-Time Polymerase Chain Reaction Serum Woman
The primary outcome was the development of HRV. Follow-up duration was measured from the date of the end of PEG-IFN treatment (EOT) to the date of HRV or the last follow-up visit. Consolidation treatment duration was measured from the date of HBsAg loss to the date of EOT. Confirmed HBsAg loss (CHL) was defined as two negative HBsAg results (<0.05 IU/mL) at least 6 months apart; HRV was defined as the reappearance of HBsAg after HBsAg loss. PEG-IFN monotherapy was defined as PEG-IFN therapy in naïve chronic hepatitis B (CHB) patients. Add-on PEG-IFN was defined as combination therapy after at least 48 weeks of nucleot(s)ide therapy. Switch-to PEG-IFN was defined as PEG-IFN monotherapy in patients who received NAs for at least 48 weeks.
Full text: Click here
Publication 2023
Combined Modality Therapy Hepatitis B, Chronic Hepatitis B Surface Antigens Patients Therapeutics
A retrospective cohort study was performed in Huashan Hospital from Jan 2014 to Dec 2019. A total of 163 chronic hepatitis B (CHB) patients who had at least one undetectable HBsAg result were consecutively enrolled, and those 112 patients who achieved PEG-IFN-induced HBsAg loss were ultimately analyzed. Exclusion criteria were NAs-induced HBsAg loss; conventional IFN-induced HBsAg loss; unconfirmed HBsAg loss (Figure 1). The study was approved by the Ethics Committee of Huashan Hospital of Fudan University and carried out in accordance with the current version of the Helsinki Declaration.
Full text: Click here
Publication 2023
Ethics Committees, Clinical Hepatitis B, Chronic Hepatitis B Surface Antigens Patients
Sera samples were tested for anti-HCV using automated CMIA (Lai Bo Biotechnology, Inc. Jinan, China). The samples were considered positive when the results exceeded the cutoff (s/co) value of 1.00 (according to the manufacturer’s recommendations). The positive samples were subsequently tested for HCV core antigen (HCV cAg; Lai Bo Biotechnology, Inc. Jinan, China), hepatitis B surface antigen (HBsAg, SYSMEX CORPORATION, Janpan), HIV antigen + antibody (Ag + Ab; SYSMEX CORPORATION, Janpan), syphilis antibody (anti-TP; Lai Bo Biotechnology, Inc. Jinan, China), anti-hepatitis A virus (HAV) IgM, and anti-hepatitis E virus (HEV) IgM (Xiamen Innodx Biotech Co., Ltd., Xiamen, China).
Full text: Click here
Publication 2023
anti-IgM Antigens Hepatitis A virus Hepatitis B Surface Antigens Hepatitis C Antibodies Hepatitis E virus HIV Antibodies Immunoglobulins Serum Syphilis

Top products related to «Hepatitis B Surface Antigens»

Sourced in United States, Germany, Ireland, Japan, France, Finland, Israel
The Architect i2000SR is a clinical chemistry analyzer designed for high-throughput testing in laboratories. It is capable of performing a wide range of clinical chemistry tests, including those for the diagnosis and monitoring of various medical conditions. The Architect i2000SR is designed to provide accurate and reliable results, with the ability to handle a large volume of samples efficiently.
Sourced in United States, Switzerland, Germany, Japan, China
The COBAS TaqMan HBV Test is a quantitative in vitro diagnostic test used for the detection and quantitation of hepatitis B virus (HBV) DNA in human serum or plasma. The test utilizes real-time PCR technology to provide accurate and reliable measurements of HBV DNA levels.
Sourced in United States, Germany, Japan, United Kingdom, Ireland
The ARCHITECT i2000 is an automated diagnostic instrument designed for clinical laboratory testing. It is capable of performing a wide range of clinical chemistry and immunoassay analyses using a variety of sample types. The ARCHITECT i2000 is a fully integrated system that automates sample handling, reagent storage, and analytical processing to provide fast and accurate test results.
Sourced in France, United States
Monolisa HBsAg ULTRA is a laboratory diagnostic kit used for the detection of the hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The kit utilizes an enzyme-linked immunosorbent assay (ELISA) technique to determine the presence of HBsAg, which is a marker for hepatitis B virus infection.
Sourced in United States, Germany, Japan, France
The AxSYM is a fully automated and integrated laboratory instrument designed for performing a wide range of immunoassay tests. It utilizes advanced technology to automate the entire testing process, from sample handling to result analysis. The AxSYM is capable of processing a variety of sample types, including serum, plasma, and urine, and can perform multiple tests simultaneously with high accuracy and precision.
Sourced in United States, Germany, China
The Elecsys HBsAg II quant assay is a diagnostic test used to quantitatively detect the hepatitis B surface antigen (HBsAg) in human serum or plasma samples. It is designed to provide accurate and reliable results for the monitoring and management of hepatitis B virus (HBV) infection.
Sourced in United States, Ireland
The ARCHITECT HBsAg assay is a laboratory diagnostic tool used to detect the presence of hepatitis B surface antigen (HBsAg) in human blood samples. It is designed to aid in the diagnosis and monitoring of hepatitis B virus (HBV) infection.
Sourced in United States, Germany
The Architect assay is a diagnostic laboratory instrument produced by Abbott. It is designed to perform a variety of clinical laboratory tests, including immunoassay and chemistry analyses. The Architect assay provides automated, high-throughput testing capabilities to support clinical decision-making.
Sourced in United States, Switzerland, Germany
The Cobas TaqMan is a real-time PCR system designed for in vitro diagnostic use. It provides automated sample preparation, real-time PCR amplification, and data analysis capabilities for the detection and quantification of nucleic acid targets.
Sourced in Germany, United States
The Elecsys HBsAg II is a diagnostic laboratory equipment product manufactured by Roche. It is used for the detection of hepatitis B surface antigen (HBsAg) in human serum and plasma samples. The Elecsys HBsAg II provides a quantitative determination of HBsAg levels, which is a key marker for the diagnosis and monitoring of hepatitis B infection.

More about "Hepatitis B Surface Antigens"

Hepatits B, HBV, hepatitis B surface antigen, HBsAg, diagnostic marker, disease progression, treatment response, Architect i2000SR, COBAS TaqMan HBV Test, ARCHITECT i2000, Monolisa HBsAg ULTRA, AxSYM, Elecsys HBsAg II quant assay, ARCHITECT HBsAg assay, Architect assay, Cobas TaqMan, Elecsys HBsAg II, PubCompare.ai, research protocols, optimization, AI-driven platform, literature, pre-prints, patents, comparison, workflow, streamlining, viral marker